Arcus Biosciences, Inc.
RCUS
$9.16
$0.030.33%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -69.26% | 7.82% | 7.85% | 13.24% | 17.20% |
| Total Depreciation and Amortization | 11.11% | 25.00% | 66.67% | 28.57% | 28.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.05% | 26.56% | 20.90% | 20.59% | 17.14% |
| Change in Net Operating Assets | 131.43% | 130.99% | 130.88% | 5.32% | 37.50% |
| Cash from Operations | -42.86% | 44.44% | 45.14% | 19.28% | 33.12% |
| Capital Expenditure | 88.00% | 75.00% | 38.89% | -100.00% | -316.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 251.90% | -135.78% | -141.56% | -120.00% | -690.00% |
| Cash from Investing | 212.50% | -143.30% | -150.23% | -129.78% | -550.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -42.53% | 618.18% | 558.33% | 630.30% | 1,764.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -27.20% | 739.39% | 587.80% | 531.58% | 1,273.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 113.21% | 129.11% | 150.00% | -72.09% | 82.96% |